{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:04:18Z","timestamp":1785863058325,"version":"3.56.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s43440-026-00861-7","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:57:15Z","timestamp":1778741835000},"page":"1208-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clozapine levels in inpatients with schizophrenia are not a predictor of rehospitalization: a naturalistic retrospective study"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-5320","authenticated-orcid":false,"given":"Anna","family":"Mach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7432-3449","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Bie\u0144kowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-2519","authenticated-orcid":false,"given":"Anna","family":"Wnorowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0108-0255","authenticated-orcid":false,"given":"Mateusz","family":"Sypniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-6761","authenticated-orcid":false,"given":"Maria","family":"Radziwo\u0144-Zaleska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-0597","authenticated-orcid":false,"given":"Andrzej","family":"Pilc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5138-9050","authenticated-orcid":false,"given":"Marcin","family":"Wojnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"3","key":"861_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40263-017-0411-6","volume":"31","author":"DM Taylor","year":"2017","unstructured":"Taylor DM. Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard? CNS Drugs. 2017;31(3):177\u201380.","journal-title":"CNS Drugs"},{"issue":"7","key":"861_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients with Schizophrenia. JAMA Psychiatry. 2017;74(7):686\u201393.","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"861_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00127-022-02220-2","volume":"57","author":"Z Zukowska","year":"2022","unstructured":"Zukowska Z, Allan S, Eisner E, Ling L, Gumley A. Fear of Relapse in Schizophrenia: A Mixed-Methods Systematic Review. Soc Psychiatry Psychiatr Epidemiol. 2022;57(7):1305\u201318.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"861_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s12888-021-03634-z","volume":"21","author":"KT J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen KT, B\u00f8g M, Kabra M, Simonsen J, Adair M, J\u00f6nsson L. Predicting Time to Relapse in Patients with Schizophrenia According to Patients\u2019 Relapse History: A Historical Cohort Study Using Real-World Data in Sweden. BMC Psychiatry. 2021;21(1):634.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"861_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/0269881116642745","volume":"30","author":"SH Gee","year":"2016","unstructured":"Gee SH, Shergill SS, Taylor DM. Factors Associated with Changes in Hospitalisation in Patients Prescribed Clozapine. J Psychopharmacol (Oxford England). 2016;30(8):819\u201325.","journal-title":"J Psychopharmacol (Oxford England)"},{"issue":"4","key":"861_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/0269881118817387","volume":"33","author":"J Kesserwani","year":"2019","unstructured":"Kesserwani J, Kadra G, Downs J, Shetty H, MacCabe JH, Taylor D, et al. Risk of Readmission in Patients with Schizophrenia and Schizoaffective Disorder Newly Prescribed Clozapine. J Psychopharmacol (Oxford England). 2019;33(4):449\u201358.","journal-title":"J Psychopharmacol (Oxford England)"},{"issue":"4","key":"861_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/acps.12700","volume":"135","author":"R Land","year":"2017","unstructured":"Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth SA. The Impact of Clozapine on Hospital Use: A Systematic Review and Meta-Analysis. Acta Psychiatr Scand. 2017;135(4):296\u2013309.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"861_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1726-4901(09)70254-0","volume":"69","author":"C-H Lin","year":"2006","unstructured":"Lin C-H, Lin S-C, Chen M-C, Wang S-Y. Comparison of Time to Rehospitalization among Schizophrenic Patients Discharged on Typical Antipsychotics, Clozapine or Risperidone. J Chin Med Assoc. 2006;69(6):264\u20139.","journal-title":"J Chin Med Assoc"},{"issue":"9","key":"861_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2165\/00023210-200418090-00005","volume":"18","author":"BJ Kinon","year":"2004","unstructured":"Kinon BJ, Ahl J, Stauffer VL, Hill AL, Buckley PF. Dose Response and Atypical Antipsychotics in Schizophrenia. CNS Drugs. 2004;18(9):597\u2013616.","journal-title":"CNS Drugs"},{"issue":"2","key":"861_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1625-6388","volume":"55","author":"J de Leon","year":"2022","unstructured":"de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Sepp\u00e4l\u00e4 N, et al. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, Crp, and Clozapine Levels. Pharmacopsychiatry. 2022;55(2):73\u201386.","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"861_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.schres.2006.01.011","volume":"83","author":"Y-Q Xiang","year":"2006","unstructured":"Xiang Y-Q, Zhang Z-J, Weng Y-Z, Zhai Y-M, Li W-B, Cai Z-J, et al. Serum Concentrations of Clozapine and Norclozapine in the Prediction of Relapse of Patients with Schizophrenia. Schizophr Res. 2006;83(2):201\u201310.","journal-title":"Schizophr Res"},{"issue":"2","key":"861_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/00007691-200304000-00019","volume":"25","author":"S Ulrich","year":"2003","unstructured":"Ulrich S, Wolf R, Staedt J. Serum Level of Clozapine and Relapse. Ther Drug Monit. 2003;25(2):252\u20135.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"861_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1055\/s-0030-1267178","volume":"44","author":"V Stieffenhofer","year":"2011","unstructured":"Stieffenhofer V, Saglam H, Schmidtmann I, Silver H, Hiemke C, Konrad A. Clozapine Plasma Level Monitoring for Prediction of Rehospitalization Schizophrenic Outpatients. Pharmacopsychiatry. 2011;44(2):55\u20139.","journal-title":"Pharmacopsychiatry"},{"issue":"12","key":"861_CR14","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/phar.2887","volume":"43","author":"JG Leung","year":"2023","unstructured":"Leung JG, Zhang L, Markota M, Ellingrod VL, Gerberi DJ, Bishop JR. A Systematic Review of Clozapine-Associated Inflammation and Related Monitoring. Pharmacotherapy. 2023;43(12):1364\u201396.","journal-title":"Pharmacotherapy"},{"key":"861_CR15","doi-asserted-by":"crossref","unstructured":"Mach A, Wnorowska A, Siwek M, Wojnar M, Radziwo\u0144-Zaleska M. Clinical and pharmacological factors influencing serum clozapine and norclozapine levels. Front Pharmacol. 2024;15.","DOI":"10.3389\/fphar.2024.1356813"},{"issue":"1","key":"861_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/YIC.0b013e32835ac9da","volume":"28","author":"AP Rajkumar","year":"2013","unstructured":"Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical Predictors of Serum Clozapine Levels in Patients with Treatment-Resistant Schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50\u20136.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1\u201302","key":"861_CR17","first-page":"63","volume":"51","author":"J de Leon","year":"2018","unstructured":"de Leon J. A Critical Commentary on the 2017 Agnp Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology. Pharmacopsychiatry. 2018;51(1\u201302):63\u20138.","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"861_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40262-023-01247-1","volume":"62","author":"F Tralongo","year":"2023","unstructured":"Tralongo F, Konecki C, Feliu C, Kaladjian A, Djerada Z. Association between Clozapine Plasma Concentrations and Treatment Response: A Systematic Review, Meta-Analysis and Individual Participant Data Meta-Analysis. Clin Pharmacokinet. 2023;62(6):807\u201318.","journal-title":"Clin Pharmacokinet"},{"key":"861_CR19","doi-asserted-by":"publisher","first-page":"1518739","DOI":"10.3389\/fphar.2024.1518739","volume":"15","author":"A Mach","year":"2024","unstructured":"Mach A, Wnorowska A, Siwek M, Wojnar M, Radziwo\u0144-Zaleska M. The Effects of Clinical and Pharmacological Factors on the Ratio of Clozapine to Norclozapine in Psychiatric Patients. Front Pharmacol. 2024;15:1518739.","journal-title":"Front Pharmacol"},{"key":"861_CR20","first-page":"293","volume":"268","author":"CJ Ruan","year":"2024","unstructured":"Ruan CJ, Olmos I, Ricciardi C, Schoretsanitis G, Vincent PD, An\u0131l Ya\u011fc\u0131o\u011flu AE, et al. Exploring Low Clozapine C\/D Ratios, Inverted Clozapine-Norclozapine Ratios and Undetectable Concentrations as Measures of Non-Adherence in Clozapine Patients: A Literature Review and a Case Series of 17 Patients from 3 Studies. Schizophr Res. 2024;268:293\u2013301.","journal-title":"Schizophr Res"},{"key":"861_CR21","doi-asserted-by":"publisher","first-page":"111583","DOI":"10.1016\/j.pnpbp.2025.111583","volume":"144","author":"B Pani\u0107","year":"2026","unstructured":"Pani\u0107 B, Luki\u0107 V, Vu\u010di\u0107evi\u0107 K, Miljkovi\u0107 B, Milovanovi\u0107 S, Jovanovi\u0107 M. Population Pharmacokinetic Analysis for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Adult Psychiatric Patients. Prog Neuropsychopharmacol Biol Psychiatry. 2026;144:111583.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"861_CR22","first-page":"14","volume":"24","author":"V Petrovic","year":"2026","unstructured":"Petrovic V, Cohen D, Bankovic D, Radmanovic B, Ignjatovic Ristic D. Clozapine (and Norclozapine) Concentrations Are Correlated with Functioning, Disability and Side-Effects When Patients Are Treated with Clozapine without the Availability of Therapeutic Drug Monitoring: A Study of Treatment-Resistant Schizophrenia Inpatients. Biomed Rep. 2026;24(1):14.","journal-title":"Biomed Rep"},{"key":"861_CR23","doi-asserted-by":"publisher","first-page":"103865","DOI":"10.1016\/j.ajp.2023.103865","volume":"91","author":"J Ding","year":"2024","unstructured":"Ding J, Liu J, Zhang Y, Xing H, Zhang Y, Li L, et al. A Retrospective Study of Clozapine and Norclozapine Concentration in Patients with Schizophrenia: Data from the Therapeutic Drug Monitoring Service, 2019\u20132022. Asian J Psychiatr. 2024;91:103865.","journal-title":"Asian J Psychiatr"},{"issue":"1","key":"861_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00213-017-4767-6","volume":"235","author":"G Kadra","year":"2018","unstructured":"Kadra G, Stewart R, Shetty H, MacCabe JH, Chang CK, Kesserwani J, et al. Antipsychotic Polypharmacy Prescribing and Risk of Hospital Readmission. Psychopharmacology. 2018;235(1):281\u20139.","journal-title":"Psychopharmacology"},{"issue":"5","key":"861_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen J, Taipale H, Meht\u00e4l\u00e4 J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy Vs Monotherapy with Psychiatric Rehospitalization among Adults with Schizophrenia. JAMA Psychiatry. 2019;76(5):499\u2013507.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"861_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1176\/ajp.156.6.863","volume":"156","author":"RR Conley","year":"1999","unstructured":"Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization Rates of Patients Recently Discharged on a Regimen of Risperidone or Clozapine. Am J Psychiatry. 1999;156(6):863\u20138.","journal-title":"Am J Psychiatry"},{"key":"861_CR27","unstructured":"WHO. The Icd-10 classification of mental and behavioural disorders. 1993."},{"issue":"1\u201302","key":"861_CR28","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"861_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","volume":"19","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, et al. Tdm in Psychiatry and Neurology: A Comprehensive Summary of the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology, Update 2017. World J Biol Psychiatry. 2018;19(3):162\u201374.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"861_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","volume":"21","author":"I Gaertner","year":"2001","unstructured":"Gaertner I, Gaertner HJ, Vonthein R, Dietz K. Therapeutic Drug Monitoring of Clozapine in Relapse Prevention: A Five-Year Prospective Study. J Clin Psychopharmacol. 2001;21(3):305\u201310.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"861_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5414\/CPP41003","volume":"41","author":"S Ulrich","year":"2003","unstructured":"Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B, et al. Therapeutic Drug Monitoring of Clozapine and Relapse\u2013a Retrospective Study of Routine Clinical Data. Int J Clin Pharmacol Ther. 2003;41(1):3\u201313.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"861_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000507638","volume":"89","author":"J de Leon","year":"2020","unstructured":"de Leon J, Ruan CJ, Schoretsanitis G, De Las Cuevas C. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. Psychother Psychosom. 2020;89(4):200\u201314.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"861_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","volume":"9","author":"A Semahegn","year":"2020","unstructured":"Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic Medication Non-Adherence and Its Associated Factors among Patients with Major Psychiatric Disorders: A Systematic Review and Meta-Analysis. Sys Rev. 2020;9(1):17.","journal-title":"Sys Rev"},{"issue":"1","key":"861_CR34","first-page":"11","volume":"48","author":"FA Mustafa","year":"2015","unstructured":"Mustafa FA, Burke JG, Abukmeil SS, Scanlon JJ, Cox M. Schizophrenia Past Clozapine: Reasons for Clozapine Discontinuation, Mortality, and Alternative Antipsychotic Prescribing. Pharmacopsychiatry. 2015;48(1):11\u20134.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"861_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s002130050028","volume":"148","author":"E Spina","year":"2000","unstructured":"Spina E, Avenoso A, Facciol\u00e0 G, Scordo MG, Ancione M, Madia AG, et al. Relationship between Plasma Concentrations of Clozapine and Norclozapine and Therapeutic Response in Patients with Schizophrenia Resistant to Conventional Neuroleptics. Psychopharmacology. 2000;148(1):83\u20139.","journal-title":"Psychopharmacology"},{"issue":"4","key":"861_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/YIC.0b013e32819f8f17","volume":"22","author":"B Yusufi","year":"2007","unstructured":"Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, et al. Prevalence and Nature of Side Effects During Clozapine Maintenance Treatment and the Relationship with Clozapine Dose and Plasma Concentration. Int Clin Psychopharmacol. 2007;22(4):238\u201343.","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"861_CR37","doi-asserted-by":"publisher","first-page":"e2438358","DOI":"10.1001\/jamanetworkopen.2024.38358","volume":"7","author":"A Hamina","year":"2024","unstructured":"Hamina A, Taipale H, Lieslehto J, L\u00e4hteenvuo M, Tanskanen A, Mittendorfer-Rutz E, et al. Comparative Effectiveness of Antipsychotics in Patients with Schizophrenia Spectrum Disorder. JAMA Netw Open. 2024;7(10):e2438358\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"861_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0706743717718167","volume":"62","author":"D Siskind","year":"2017","unstructured":"Siskind D, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Can J Psychiatry. 2017;62(11):772\u20137.","journal-title":"Can J Psychiatry"},{"issue":"3","key":"861_CR39","first-page":"Cd006324","volume":"3","author":"S Barber","year":"2017","unstructured":"Barber S, Olotu U, Corsi M, Cipriani A. Clozapine Combined with Different Antipsychotic Drugs for Treatment-Resistant Schizophrenia. Cochrane Database Syst Rev. 2017;3(3):Cd006324.","journal-title":"Cochrane Database Syst Rev"},{"key":"861_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.euroneuro.2022.03.010","volume":"59","author":"SW Joo","year":"2022","unstructured":"Joo SW, Kim H, Jo YT, Ahn S, Choi YJ, Choi W, et al. Comparative Effectiveness of Antipsychotic Monotherapy and Polypharmacy in Schizophrenia Patients with Clozapine Treatment: A Nationwide, Health Insurance Data-Based Study. Eur Neuropsychopharmacol. 2022;59:36\u201344.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"861_CR41","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.euroneuro.2015.04.027","volume":"25","author":"B Sneider","year":"2015","unstructured":"Sneider B, Pristed SG, Correll CU, Nielsen J. Frequency and Correlates of Antipsychotic Polypharmacy among Patients with Schizophrenia in Denmark: A Nation-Wide Pharmacoepidemiological Study. Eur Neuropsychopharmacol. 2015;25(10):1669\u201376.","journal-title":"Eur Neuropsychopharmacol"},{"key":"861_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.schres.2019.05.030","volume":"209","author":"K Matsui","year":"2019","unstructured":"Matsui K, Tokumasu T, Takekita Y, Inada K, Kanazawa T, Kishimoto T, et al. Switching to Antipsychotic Monotherapy Vs. Staying on Antipsychotic Polypharmacy in Schizophrenia: A Systematic Review and Meta-Analysis. Schizophr Res. 2019;209:50\u20137.","journal-title":"Schizophr Res"},{"issue":"12","key":"861_CR43","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/17425255.2020.1821646","volume":"16","author":"JM Azorin","year":"2020","unstructured":"Azorin JM, Simon N. Antipsychotic Polypharmacy in Schizophrenia: Evolving Evidence and Rationale. Expert Opin Drug Metab Toxicol. 2020;16(12):1175\u201386.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"861_CR44","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","volume":"72","author":"O Agid","year":"2011","unstructured":"Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, et al. An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates over 3 Prospective Antipsychotic Trials with a Retrospective Data Analysis. J Clin Psychiatry. 2011;72(11):1439\u201344.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"861_CR45","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/ijnp\/pyad053","volume":"26","author":"TC Lin","year":"2023","unstructured":"Lin TC, Lin CH. Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics from a Public Psychiatric Hospital in Taiwan, 2006\u20132021. Int J Neuropsychopharmacol. 2023;26(11):808\u201316.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"861_CR46","doi-asserted-by":"publisher","first-page":"23m15071","DOI":"10.4088\/JCP.23m15071","volume":"85","author":"Y Tien","year":"2024","unstructured":"Tien Y, Wang XY, Huang SC, Huang HP. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients with Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study. J Clin Psychiatry. 2024;85(2):23m15071.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"861_CR47","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1192\/bjo.2019.97","volume":"6","author":"K Hariman","year":"2020","unstructured":"Hariman K, Cheng KM, Lam J, Leung SK, Lui SSY. Clinical Risk Model to Predict 28-Day Unplanned Readmission Via the Accident and Emergency Department after Discharge from Acute Psychiatric Units for Patients with Psychotic Spectrum Disorders. BJPsych Open. 2020;6(1):e13.","journal-title":"BJPsych Open"},{"key":"861_CR48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.genhosppsych.2015.10.009","volume":"39","author":"V Donisi","year":"2016","unstructured":"Donisi V, Tedeschi F, Salazzari D, Amaddeo F. Pre- and Post-Discharge Factors Influencing Early Readmission to Acute Psychiatric Wards: Implications for Quality-of-Care Indicators in Psychiatry. Gen Hosp Psychiatry. 2016;39:53\u20138.","journal-title":"Gen Hosp Psychiatry"},{"issue":"6","key":"861_CR49","doi-asserted-by":"publisher","first-page":"e011060","DOI":"10.1136\/bmjopen-2016-011060","volume":"6","author":"H Zhou","year":"2016","unstructured":"Zhou H, Della PR, Roberts P, Goh L, Dhaliwal SS. Utility of Models to Predict 28-Day or 30-Day Unplanned Hospital Readmissions: An Updated Systematic Review. BMJ Open. 2016;6(6):e011060.","journal-title":"BMJ Open"},{"key":"861_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","volume":"5","author":"PM Haddad","year":"2014","unstructured":"Haddad PM, Brain C, Scott J. Nonadherence with Antipsychotic Medication in Schizophrenia: Challenges and Management Strategies. Patient Relat Outcome Meas. 2014;5:43\u201362.","journal-title":"Patient Relat Outcome Meas"},{"issue":"12","key":"861_CR51","first-page":"1225","volume":"64","author":"TL Boaz","year":"2013","unstructured":"Boaz TL, Becker MA, Andel R, Van Dorn RA, Choi J, Sikirica M, Washington. D C). 2013;64(12):1225\u20139.","journal-title":"D C)"},{"key":"861_CR52","doi-asserted-by":"crossref","unstructured":"Addington DE, Patten SB, McKenzie E, Addington J. Relationship between Relapse and Hospitalization in First-Episode Psychosis. Psychiatr Serv (Washington D C). 2013;64(8):796\u20139.","DOI":"10.1176\/appi.ps.201200440"},{"issue":"4","key":"861_CR53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5152\/pcp.2025.24981","volume":"35","author":"P Pfeifer","year":"2025","unstructured":"Pfeifer P, Mathys B, Alan EM, Bracht T, Choinowski S, Adorjan K, et al. Therapeutic Drug Monitoring of Psychotropic Drugs in Inpatient Psychiatry: Local Practice and Improvement. Psychiatry Clin Psychopharmacol. 2025;35(4):389\u201395.","journal-title":"Psychiatry Clin Psychopharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00861-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00861-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00861-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:03:20Z","timestamp":1785859400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00861-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00861-7","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving humans were approved by the local Ethics Committee at the Medical University of Warsaw (approval No. AKBE\/83\/2021). The studies were conducted in accordance with the local legislation and institutional requirements. No written informed consent was required for this study from either the study participants or the participants\u2019 legal guardians\/next of kin; this is in accordance with the national legislation and institutional requirements.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}